 |
 |
 |
 |
 |
 |
TORONTO, Canada, October 3, 2023 – The Structural Genomics Consortium (SGC) today announced that it has entered into a partnership with Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH). HitGen will utilize its DNA-encoded library (DEL) technology platform, specifically OpenDEL™, to screen under-represented targets chosen by SGC.
At Structural Genomics Consortium, we are committed to driving advancements in basic and biomedical research that can positively impact the world. We believe that collaborative efforts and innovative solutions are essential for achieving groundbreaking discoveries. Today, we invite researchers from all corners of the globe to stand united in support of renewable antibody resources.
Sign the Petition to Prioritize Renewable Antibody Resources!
Have you ever experienced any of the following research roadblocks?
1. Wasted resources on a commercial antibody that did not perform as claimed?
Trainees are an integral part of the 20 years SGC global network of over 250 scientists. Since 2015, we've proudly partnered with Mitacs, offering over 550 internship units to trainees across 25+ unique projects, totaling $8.4M. This direct support funds trainee stipends and research costs.
North Carolina, May 10, 2023 – The Structural Genomics Consortium (SGC) at the University of North Carolina at Chapel Hill has been awarded a $1.5 million grant from the U.S Department of Defense to support drug discovery efforts aimed at the investigation of small molecules that could potentially serve as new treatment options for patients with Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s Disease.
The University of Toronto's Acceleration Consortium has received a record-breaking $200 million Canada First Research Excellence Fund (CFREF) to advance the discovery of new materials and molecules. This award marks the largest single federal research grant to a university in Canadian history.
December 4-7
Brisbane, Australia
Target 2035 will be featured at the ICBS Annual Conference on December 6. Don’t delay – submit your abstract by September 30.
For more information, visit ICBS2022.
SGC CEO, Aled Edwards, and Cheryl Arrowsmith, Chief Scientist for the Structural Genomics Consortium (SGC) Toronto laboratories are featured in a piece by the Institute for Protein Innovation discussing Target 2035- a remarkable initiative connecting scientists globally in the quest to study every human protein by 2035.
Read the Institute for Protein Innovation article.
Cheryl Arrowsmith, Chief Scientist for the Structural Genomics Consortium (SGC) Toronto laboratories, and Paul Workman, Professor of Pharmacology and Therapeutics at the Institute of Cancer Research (ICR) in London, talked to Nature Communications about chemical probes, their respective paths to leadership positions in the field, the online resources available to those interested in the topic and the promise and value of open — collaborative — science.
Toronto, May 16, 2022 – An article published today in the journal Nature Chemical Biology reveals a mechanism of antitumor activity for triple negative breast cancer, which is the most aggressive breast cancer subtype with less promising prognosis and with few effective therapies.
